Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: CDK7-targeted therapy effectively disrupts cell cycle progression and oncogenic signaling in head and neck cancer

Fig. 5

Impact of CDK7 inhibition on in vivo xenograft models. a Tumor growth of FaDu and HCA-LSC1 cell lines with CDK7 KO or empty vector (n = 12 tumors per group for FaDu xenografts, and n = 7 tumors per group for HCA-LSC1 xenografts). Data shown as mean ± SEM. Statistic two-way ANOVA, uncorrected Fisher’s LSD, ***p < 0.001. b Box plots representing final tumor volumes of CDK7 KO or empty vector groups. Unpaired t-test, ***p < 0.001. c, d Schematic representation of YKL-5-124 (c) and samuraciclib (d) testing in vivo. Created in https://BioRender.com. e, f Tumor growth of FaDu and HCA-LSC1 cell lines in presence of vehicle/YKL-5-124 (n = 12 tumors per treatment condition) (e) or vehicle/samuraciclib (n = 12 tumors per condition) (f) treatment for 12 days. Arrows indicate start of treatment. Data shown as mean ± SEM. Statistic two-way ANOVA, uncorrected Fisher’s LSD, ***p < 0.001. g Box plots representing final tumor volumes among the different experimental groups within pharmacological CDK7 inhibition experiments. Unpaired t-test, ***p < 0.001

Back to article page